Introduction {#s1}
============

Although estimated to cause the ninth largest disease burden among individual infectious diseases, leishmaniasis is largely ignored in discussions of tropical disease priorities [@pone.0035671-Hotez1], [@pone.0035671-Hotez2]. This consignment to critical oblivion results from its complex epidemiology and ecology, the lack of simple, easily-applied tools for case management and the paucity of current incidence data, and often results in a failure on the part of policy-makers to recognize its importance [@pone.0035671-Alvar1], [@pone.0035671-Bern1]. Based on the World Health Assembly Resolution 2007/60.13, the World Health Organization (WHO) convened the Expert Committee on Leishmaniasis in March 2010, which subsequently issued the first updated technical report on leishmaniasis in more than 20 years [@pone.0035671-World1], [@pone.0035671-World2]. Both the WHA Resolution and the Expert Committee report highlighted the need to update the epidemiological evidence base in order to plan appropriate approaches to the control of leishmaniasis.

Estimates of disease burden are widely used by policy-makers and funding organizations to establish priorities [@pone.0035671-Murray1], [@pone.0035671-Cattand1], [@pone.0035671-Mathers1], [@pone.0035671-World3]. These estimates are most commonly expressed as disability-adjusted life years (DALYs) lost, a measurement first promoted in the 1993 World Development Report and the focus of intense scrutiny ever since [@pone.0035671-World4], [@pone.0035671-AbouZahr1], [@pone.0035671-King1]. The accuracy of this measure depends on the reliability of the incidence, duration, severity and mortality data for a given condition, as well as the underlying assumptions used in the calculations [@pone.0035671-Murray1], [@pone.0035671-King2]. Although a new round of global disease burden estimation is currently underway, empirical data collection and field validation are neither included nor supported as part of the exercise [@pone.0035671-Institute1].

10.1371/journal.pone.0035671.t001

###### Reported and estimated incidence of visceral leishmaniasis in the American region.

![](pone.0035671.t001){#pone-0035671-t001-1}

                 Reported VL cases/year   Years of report   Estimated annual VL incidence       
  ------------- ------------------------ ----------------- ------------------------------- ---- --------------------------------------
  Argentina                8                2004--2008                   20                 to    30[1](#nt101){ref-type="table-fn"}
  Bolivia                  0                   2008                                             
  Brazil                  3481              2003--2007                  4200                to   6300[2](#nt102){ref-type="table-fn"}
  Colombia                 60               2004--2008                   70                 to   110[2](#nt102){ref-type="table-fn"}
  El Salvador                                 no data                                           
  Guatemala                15               2004--2008                   20                 to    30[2](#nt102){ref-type="table-fn"}
  Honduras                 6                2004--2008                    7                 to    10[2](#nt102){ref-type="table-fn"}
  Mexico                   7                2004--2008                    8                 to    12[2](#nt102){ref-type="table-fn"}
  Nicaragua                3                2003--2007                    3                 to    5[2](#nt102){ref-type="table-fn"}
  Paraguay                 48               2004--2008                   100                to   200[1](#nt101){ref-type="table-fn"}
  Venezuela                40               2004--2008                   50                 to    70[2](#nt102){ref-type="table-fn"}
  Region                  3668                                          4500                to                   6800

Underreporting considered moderate (2--4-fold) based on recent introduction of VL into the country.

Underreporting considered mild (1.2--1.8-fold) based on data from Brazil [@pone.0035671-MaiaElkhoury1].

10.1371/journal.pone.0035671.t002

###### Reported and estimated incidence of visceral leishmaniasis in the sub-Saharan African region.

![](pone.0035671.t002){#pone-0035671-t002-2}

                              Reported VL cases/year   Years of report   Estimated annual VL incidence     
  -------------------------- ------------------------ ----------------- ------------------------------- -- --
  Central African Republic                                 no data                                         
  Cameroon                                                 no data                                         
  Chad                                                     no data                                         
  Cote d'Ivoire                         0                2004--2008                                        
  DR Congo                              0                2004--2008                                        
  Gambia                                                   no data                                         
  Mauritania                                               no data                                         
  Niger                                                    no data                                         
  Nigeria                               1                2004--2008                                        
  Senegal                               0                2004--2008                                        
  Zambia                                                   no data                                         
  Region                                1                                                                  

10.1371/journal.pone.0035671.t003

###### Reported and estimated incidence of visceral leishmaniasis in the East African region.

![](pone.0035671.t003){#pone-0035671-t003-3}

                 Reported VL cases/year   Years of report   Estimated annual VL incidence       
  ------------- ------------------------ ----------------- ------------------------------- ---- ----------------------------------------
  Djibouti                                    no data                                           
  Eritrea                 100                  2008                      200                to    400[1](#nt103){ref-type="table-fn"}
  Ethiopia                1860              2004--2008                  3700                to    7400[1](#nt103){ref-type="table-fn"}
  Kenya                   145               2004--2008                   610                to    1200[2](#nt104){ref-type="table-fn"}
  Somalia                 679                  2009                     1400                to    2700[1](#nt103){ref-type="table-fn"}
  Sudan                   3742              2005--2009                 15,700               to   30,300[2](#nt104){ref-type="table-fn"}
  South Sudan             1756              2004--2008                  7400                to   14,200[2](#nt104){ref-type="table-fn"}
  Uganda                  288               2004--2008                   350                to    520[3](#nt105){ref-type="table-fn"}
  Region                  8569                                         29,400               to                   56,700

Underreporting considered moderate (2--4-fold).

Underreporting considered severe (4.2--8.1-fold).

Underreporting considered mild (1.2--1.8).

10.1371/journal.pone.0035671.t004

###### Reported and estimated incidence of visceral leishmaniasis in the Mediterranean region.

![](pone.0035671.t004){#pone-0035671-t004-4}

                            Reported VL cases/year   Years of report   Estimated annual VL incidence       
  ------------------------ ------------------------ ----------------- ------------------------------- ---- -------------------------------------
  Albania                            114               2004--2008                   140                to   210[1](#nt106){ref-type="table-fn"}
  Algeria                            111               2004--2008                   130                to   200[1](#nt106){ref-type="table-fn"}
  Bosnia and Herzegovina              2                2002--2005                    2                 to    3[1](#nt106){ref-type="table-fn"}
  Bulgaria                            7                2004--2008                    8                 to   12[1](#nt106){ref-type="table-fn"}
  Croatia                             5                2004--2008                    6                 to    8[1](#nt106){ref-type="table-fn"}
  Cyprus                              2                   2008                       2                 to    4[1](#nt106){ref-type="table-fn"}
  Egypt                               1                   2008                       1                 to    2[1](#nt106){ref-type="table-fn"}
  France                              18               2004--2008                   20                 to   30[1](#nt106){ref-type="table-fn"}
  Greece                              42               2004--2008                   50                 to   80[1](#nt106){ref-type="table-fn"}
  Israel                              2                2003--2007                    3                 to    4[1](#nt106){ref-type="table-fn"}
  Italy                              134               2003--2007                   160                to   240[1](#nt106){ref-type="table-fn"}
  Jordan                              0                2004--2008                    0                 to                    0
  Lebanon                             0                2004--2008                    0                 to                    0
  Libya                               3                2004--2008                    5                 to   10[2](#nt107){ref-type="table-fn"}
  Macedonia                           7                2005--2009                    9                 to   13[1](#nt106){ref-type="table-fn"}
  Malta                               2                2002--2005                    3                 to    4[1](#nt106){ref-type="table-fn"}
  Monaco                                                 no data                                           
  Montenegro                          3                2004--2008                    4                 to    5[1](#nt106){ref-type="table-fn"}
  Morocco                            152               2004--2008                   300                to   610[2](#nt107){ref-type="table-fn"}
  Palestine                           5                2004--2008                   10                 to   20[2](#nt107){ref-type="table-fn"}
  Portugal                            15               2003--2007                   20                 to   30[1](#nt106){ref-type="table-fn"}
  Slovenia                                               no data                                           
  Spain                              117               2004--2008                   140                to   210[1](#nt106){ref-type="table-fn"}
  Syria                               14               2004--2008                   30                 to   60[2](#nt107){ref-type="table-fn"}
  Tunisia                             89               2004--2008                   110                to   160[1](#nt106){ref-type="table-fn"}
  Turkey                              29               2003--2007                   60                 to   120[2](#nt107){ref-type="table-fn"}
  Region                             875                                           1200                                    2000

Underreporting considered mild (1.2--1.8-fold).

Underreporting considered moderate (2--4-fold).

10.1371/journal.pone.0035671.t005

###### Reported and estimated incidence of visceral leishmaniasis in the Middle East to Central Asia.

![](pone.0035671.t005){#pone-0035671-t005-5}

                                Reported VL cases/year   Years of report   Estimated annual VL incidence       
  ---------------------------- ------------------------ ----------------- ------------------------------- ---- --------------------------------------
  Afghanistan                                                no data                                           
  Armenia                                 7                2004--2008                   10                 to    30[1](#nt108){ref-type="table-fn"}
  Azerbaijan                              28               2004--2008                   60                 to   110[1](#nt108){ref-type="table-fn"}
  China                                  378               2004--2008                   760                to   1500[1](#nt108){ref-type="table-fn"}
  Georgia                                164               2004--2008                   330                to   660[1](#nt108){ref-type="table-fn"}
  Iran (Islamic Republic of)             149               2004--2008                   300                to   600[1](#nt108){ref-type="table-fn"}
  Iraq                                   1711              2004--2008                  3400                to   6800[1](#nt108){ref-type="table-fn"}
  Kazakhstan                              1                2004--2008                    2                 to    4[1](#nt108){ref-type="table-fn"}
  Kyrgyzstan                              0                2004--2008                                          
  Oman                                    1                2004--2008                    2                 to    4[1](#nt108){ref-type="table-fn"}
  Pakistan                                                   no data                                           
  Saudi Arabia                            34               2004--2008                   40                 to    60[2](#nt109){ref-type="table-fn"}
  Tajikistan                              15               2004--2008                   30                 to    60[1](#nt108){ref-type="table-fn"}
  Turkmenistan                            0                2004--2008                                          
  Ukraine                                 2                2005--2008                    4                 to    7[1](#nt108){ref-type="table-fn"}
  Uzbekistan                              7                2004--2008                   10                 to    30[1](#nt108){ref-type="table-fn"}
  Yemen                                   0                2004--2008                   20                 to    50[1](#nt108){ref-type="table-fn"}
  Region                                 2496                                          5000                                    10,000

Underreporting considered moderate (2--4-fold).

Underreporting considered mild (1.2--1.8).

10.1371/journal.pone.0035671.t006

###### Reported and estimated incidence of visceral leishmaniasis in the Indian subcontinent and Southeast Asia.

![](pone.0035671.t006){#pone-0035671-t006-6}

                Reported VL cases/year   Years of report   Estimated annual VL incidence       
  ------------ ------------------------ ----------------- ------------------------------- ---- ----------------------------------------
  Bangladesh             6224              2004--2008                 12,400               to   24,900[1](#nt110){ref-type="table-fn"}
  Bhutan                  2                2005--2009                   10                 to     20[2](#nt111){ref-type="table-fn"}
  India                 34,918             2004--2008                 146,700              to                 282,800^3^
  Nepal                  1477              2004--2008                  3000                to    5900[1](#nt110){ref-type="table-fn"}
  Sri Lanka                                  no data                     6                 to                   10^4^
  Thailand                2                2006--2010                    5                 to                   10^5^
  Region                42,623                                        162,100              to                  313,600

Underreporting considered moderate (2.0--4.0-fold; based on lower proportion of cases treated in private sector compared to India).

Underreporting range based on 2 assessments in Bihar [@pone.0035671-Singh1], [@pone.0035671-Singh2].

10.1371/journal.pone.0035671.t007

###### Reported and estimated incidence of cutaneous leishmaniasis in the American region.

![](pone.0035671.t007){#pone-0035671-t007-7}

                        Reported CL cases/year   Years of report   Estimated annual CL incidence       
  -------------------- ------------------------ ----------------- ------------------------------- ---- -----------------------------------------
  Argentina                      261               2004--2008                   730                to    1200[1](#nt112){ref-type="table-fn"}
  Belize                                             no data                                           
  Bolivia                        2647              2004--2008                  7400                to   12,200[1](#nt112){ref-type="table-fn"}
  Brazil                        26,008             2003--2007                 72,800               to   119,600[1](#nt112){ref-type="table-fn"}
  Colombia                      17,420             2005--2009                 48,800               to   80,100[1](#nt112){ref-type="table-fn"}
  Costa Rica                     1249              2002--2006                  3500                to    5700[1](#nt112){ref-type="table-fn"}
  Dominican Republic                                 no data                     0                 to                      0
  Ecuador                        1724              2004--2008                  4800                to    7900[1](#nt112){ref-type="table-fn"}
  El Salvador                                        no data                     0                 to                      0
  French Guyana                  233               2004--2008                   650                to    1100[1](#nt112){ref-type="table-fn"}
  Guatemala                      684               2004--2008                  1900                to    3100[1](#nt112){ref-type="table-fn"}
  Guyana                          16               2006--2008                   50                 to     70[1](#nt112){ref-type="table-fn"}
  Honduras                       1159              2006--2008                  3200                to    5300[1](#nt112){ref-type="table-fn"}
  Mexico                         811               2004--2008                  2300                to    3700[1](#nt112){ref-type="table-fn"}
  Nicaragua                      3222              2003--2007                  9000                to   14,800[1](#nt112){ref-type="table-fn"}
  Panama                         2188              2005--2009                  6100                to   10,100[1](#nt112){ref-type="table-fn"}
  Paraguay                       431               2004--2008                  1200                to    2000[1](#nt112){ref-type="table-fn"}
  Peru                           6405              2004--2008                 17,900               to   29,500[1](#nt112){ref-type="table-fn"}
  Suriname                        3                2005--2007                    8                 to     14[1](#nt112){ref-type="table-fn"}
  Venezuela                      2480              2004--2008                  6900                to   11,400[1](#nt112){ref-type="table-fn"}
  REGION                        66,941                                        187,200                                   307,800

Underreporting considered mild (2.8--4.6-fold) based on data from Argentina [@pone.0035671-Yadon1].

10.1371/journal.pone.0035671.t008

###### Reported and estimated incidence of cutaneous leishmaniasis in the sub-Saharan African region.

![](pone.0035671.t008){#pone-0035671-t008-8}

                   Reported CL cases/year   Years of report   Estimated annual CL incidence       
  --------------- ------------------------ ----------------- ------------------------------- ---- --------------------------------------
  Burkina Faso                                  no data                                           
  Cameroon                   55               2007--2009                   280                to   550[1](#nt113){ref-type="table-fn"}
  Chad                                          no data                                           
  Cote d'Ivoire              1                2004--2008                    5                 to    10[1](#nt113){ref-type="table-fn"}
  DR Congo                   0                   2009                                             
  Ghana                      27               2004--2008                   140                to   270[1](#nt113){ref-type="table-fn"}
  Guinea                                        no data                                           
  Guinea-Bissau                                 no data                                           
  Mali                       58               2004--2008                   290                to   580[1](#nt113){ref-type="table-fn"}
  Mauritania                                    no data                                           
  Namibia                                       no data                                           
  Niger                                         no data                                           
  Nigeria                    5                2004--2008                   30                 to    50[1](#nt113){ref-type="table-fn"}
  Senegal                    8                2004--2008                   40                 to    80[1](#nt113){ref-type="table-fn"}
  South Africa                                  no data                                           
  REGION                    155                                            790                to   1500[1](#nt113){ref-type="table-fn"}

Underreporting considered moderate (5--10-fold).

10.1371/journal.pone.0035671.t009

###### Reported and estimated incidence of cutaneous leishmaniasis in the East African region.

![](pone.0035671.t009){#pone-0035671-t009-9}

                 Reported CL cases/year   Years of report   Estimated annual CL incidence       
  ------------- ------------------------ ----------------- ------------------------------- ---- ----------------------------------------
  Djibouti                                    no data                                           
  Eritrea                  50                  2008                      250                to    500[1](#nt114){ref-type="table-fn"}
  Ethiopia                                    no data                  20,000               to   50,000[2](#nt115){ref-type="table-fn"}
  Kenya                                       no data                                           
  Sudan                                       no data                  15,000               to   40,000[3](#nt116){ref-type="table-fn"}
  South Sudan                                 no data                                           
  REGION                   50                                          35,300               to                   90,500

Underreporting considered moderate (5--10-fold).

Based on conference report (Armauer Hansen Research Institute, Federal Ministry of Health of Ethiopia and World Health Organization. Consultative meeting for the control of cutaneous leishmaniasis in Ethiopia; June 4--5, 2011; Addis Ababa, Ethiopia).

Based on estimates by Dr. Nuha Hamid, national project officer, WHO-Khartoum, Sudan (see Annex).

10.1371/journal.pone.0035671.t010

###### Reported and estimated incidence of cutaneous leishmaniasis in the Mediterranean.

![](pone.0035671.t010){#pone-0035671-t010-10}

                            Reported CL cases/year   Years of report   Estimated annual CL incidence       
  ------------------------ ------------------------ ----------------- ------------------------------- ---- -----------------------------------------
  Albania                             6                2004--2008                                          
  Algeria                           44,050             2004--2008                 123,300              to   202,600[1](#nt117){ref-type="table-fn"}
  Bosnia and Herzegovina              0                   2008                                             
  Bulgaria                            0                   2008                                             
  Croatia                             2                2004--2008                    6                 to     10[1](#nt117){ref-type="table-fn"}
  Cyprus                              1                2006--2008                                          
  Egypt                              471                  2008                     1300                to    2200[1](#nt117){ref-type="table-fn"}
  France                              2                2004--2008                    6                 to     10[1](#nt117){ref-type="table-fn"}
  Greece                              3                2004--2008                    8                 to     13[1](#nt117){ref-type="table-fn"}
  Israel                             579               2003--2007                  1600                to    2700[1](#nt117){ref-type="table-fn"}
  Italy                               49               2003--2007                   140                to     230[1](#nt117){ref-type="table-fn"}
  Jordan                             227               2004--2008                   630                to    1000[1](#nt117){ref-type="table-fn"}
  Lebanon                             0                2004--2008                                          
  Libya                              3540              2004--2008                  9900                to   16,300[1](#nt117){ref-type="table-fn"}
  Macedonia                           0                   2008                                             
  Malta                               0                   2008                                             
  Monaco                                                 no data                                           
  Montenegro                          0                   2008                                             
  Morocco                            3430              2004--2008                  9600                to   15,800[1](#nt117){ref-type="table-fn"}
  Palestine                          218               2005--2009                   610                to    1000[1](#nt117){ref-type="table-fn"}
  Portugal                            0                2004--2008                                          
  Slovenia                                               no data                                           
  Spain                               0                2004--2008                                          
  Syria                             22,882             2004--2008                 64,100               to   105,300[1](#nt117){ref-type="table-fn"}
  Tunisia                            7631              2004--2008                 21,400               to   35,100[1](#nt117){ref-type="table-fn"}
  Turkey                             2465              2003--2007                  6900                to   11,300[1](#nt117){ref-type="table-fn"}
  REGION                            85,555                                        239,500                                   393,600

Underreporting considered mild (2.8--4.6) [@pone.0035671-Yadon1].

10.1371/journal.pone.0035671.t011

###### Reported and estimated incidence of cutaneous leishmaniasis in the Middle East to Central Asia.

![](pone.0035671.t011){#pone-0035671-t011-11}

                                Reported CL cases/year   Years of report   Estimated annual CL incidence       
  ---------------------------- ------------------------ ----------------- ------------------------------- ---- -----------------------------------------
  Afghanistan                           22,620             2003--2007                 113,100              to   226,200[1](#nt118){ref-type="table-fn"}
  Armenia                                 0                   2008                                             
  Azerbijan                               17               2004--2008                   50                 to     80[2](#nt119){ref-type="table-fn"}
  China                                   0                2004--2008                                          
  Georgia                                 5                2004--2008                                          
  Iran (Islamic Republic of)            24,630             2004--2008                 69,000               to   113,300[2](#nt119){ref-type="table-fn"}
  Iraq                                   1655              2004--2008                  8300                to   16,500[3](#nt120){ref-type="table-fn"}
  Kazakhstan                              15               2004--2008                   40                 to     70[2](#nt119){ref-type="table-fn"}
  Kyrgyzstan                              0                2004--2008                                          
  Mongolia                                                   no data                                           
  Oman                                    5                2004--2008                   15                 to     20[2](#nt119){ref-type="table-fn"}
  Pakistan                               7752              2004--2008                 21,700               to   35,700[2](#nt119){ref-type="table-fn"}
  Saudi Arabia                           3445              2004--2008                  9600                to   15,800[2](#nt119){ref-type="table-fn"}
  Tajikistan                              25               2007--2008                   125                to     250[3](#nt120){ref-type="table-fn"}
  Turkmenistan                            99               2004--2008                   490                to     990[3](#nt120){ref-type="table-fn"}
  Ukraine                                 2                2004--2008                   10                 to     20[3](#nt120){ref-type="table-fn"}
  Uzbekistan                             142               2004--2008                   710                to    1400[3](#nt120){ref-type="table-fn"}
  Yemen                                  603               2005--2009                  3000                to    6000[3](#nt120){ref-type="table-fn"}
  REGION                                61,013                                        226,200                                   416,400

Underreporting considered moderate (5--10-fold) based on estimates of incidence from population-based surveys [@pone.0035671-Reithinger1].

Underreporting considered mild (2.8--4.6) [@pone.0035671-Yadon1].

Underreporting considered moderate (5--10-fold).

10.1371/journal.pone.0035671.t012

###### Reported and estimated incidence of cutaneous leishmaniasis in the Indian subcontinent.

![](pone.0035671.t012){#pone-0035671-t012-12}

               Reported CL cases/year   Years of report   Estimated annual CL incidence       
  ----------- ------------------------ ----------------- ------------------------------- ---- --------------------------------------
  India                 156               2005--2009                  1000                to   2000[1](#nt121){ref-type="table-fn"}
  Sri Lanka             322               2004--2008                   900                to   1500[2](#nt122){ref-type="table-fn"}
  REGION                478                                           1900                to                   3500

Based on estimates by Dr RA Bumb, Department of Skin, STD and Leprosy, SP Medical College, Bikaner, Rajasthan, India.

Underreporting considered mild (2.8--4.6) [@pone.0035671-Yadon1].

10.1371/journal.pone.0035671.t013

###### Global reported and estimated incidence of visceral leishmaniasis.

![](pone.0035671.t013){#pone-0035671-t013-13}

                                 Reported VL cases/year         Countries with 5 years of data         Estimated annual VL incidence       
  ----------------------------- ------------------------ -------------------------------------------- ------------------------------- ---- ---------
  Americas                                3662                            8/11 (73%)                               4500                to    6800
  Sub-Saharan Africa                       1                              3/11 (27%)                                                       
  East Africa                             8569                            5/8 (63%)                               29,400               to   56,700
  Mediterranean                           875                            21/26 (81%)                               1200                to    2000
  Middle East to Central Asia             2496                           14/17 (82%)                               5000                to   10,000
  South Asia                             42,623           3/6 (50%)[\*](#nt123){ref-type="table-fn"}              162,100              to   313,600
  Global total                           58,227                          54/79 (68%)                              202,200              to   389,100

3/3 (100%) of high burden countries (India, Bangladesh, Nepal) reported 5 years of data. Reports incomplete for Sri Lanka, Bhutan and Thailand.

10.1371/journal.pone.0035671.t014

###### Global reported and estimated incidence of cutaneous leishmaniasis.

![](pone.0035671.t014){#pone-0035671-t014-14}

                                 Reported CLcases/year   Countries with 5 yearsof data   Estimated annual CL incidence       
  ----------------------------- ----------------------- ------------------------------- ------------------------------- ---- -----------
  Americas                              66,941                    14/20 (70%)                       187,200              to    307,800
  Sub-Saharan Africa                      155                     5/15 (33%)                          770                to     1500
  East Africa                             50                       0/6 (0%)                         35,300               to    90,500
  Mediterranean                         85,555                    17/26 (65%)                       239,500              to    393,600
  Middle East to Central Asia           61,013                    16/18 (89%)                       226,200              to    416,400
  South Asia                              322                     2/2 (100%)                         1900                to     3500
  Global total                          214,036                   53/87 (61%)                       690,900              to   1,213,300
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Methods {#s2}
=======

From 2007 to 2010, WHO organized a series of regional meetings (EMRO countries, Geneva 2007; PAHO countries, Medellin 2008; EURO countries, Istanbul 2009; AFRO countries, Addis Ababa 2010; SEARO countries, Paro 2011). In preparation for each meeting, country representatives were asked to provide yearly reported VL and cutaneous leishmaniasis (CL) incidence data for at least the last 5 years prior to the meeting. In addition, an electronic epidemiological questionnaire was sent to the national control program managers and/or to reputable national scientists to fill information gaps. Data collected included administrative divisions affected, whether VL and CL case notification is mandatory, characteristics of known reservoirs and vector control programs, estimated and reported case numbers, and outbreaks in the previous 5 years.

A comprehensive literature search was also conducted, and the resulting information was used as an independent validation of these data. We reviewed the literature based on MEDLINE searches using the terms *leishmaniasis* and *epidemiology* with the name of each endemic country or territory. For the initial search, we included all articles listed in MEDLINE in English, French, Spanish or Russian up to October 2010, when the search was conducted. We selected articles that explicitly addressed incidence, geographic distribution, surveillance and/or trends over time, and preferentially chose articles published since 2000 if available. For countries with sparse data on leishmaniasis, we broadened the review to include all articles that shed light on the occurrence of the disease within that country. We reviewed titles for all references, abstracts when available for those whose titles were not sufficient to lead us to exclude the paper, and the full article when the abstract indicated possible relevance. The search for country-specific literature yielded 3242 potentially relevant articles, of which 340 were retained based on our selection criteria. Five recent review articles were also included. Twenty-six additional unpublished reports were provided by national or international experts. The literature was reviewed by at least 2 authors and regular meetings were held among the authors to discuss the findings in depth.

A MEDLINE search was also performed using the terms *leishmaniasis* and *underreporting* to identify articles that would aid in making incidence estimates. This search yielded 8 articles of which 5 presented data on the magnitude of leishmaniasis underreporting. One additional article was identified from author literature collections, yielding 3 articles with empirical data regarding VL and 3 for CL underreporting [@pone.0035671-Copeland1], [@pone.0035671-MaiaElkhoury1], [@pone.0035671-Mosleh1], [@pone.0035671-Singh1], [@pone.0035671-Singh2], [@pone.0035671-Yadon1]. These articles were used to establish probable degrees of underreporting for the countries in which their analyses were performed, and were also used for estimates in countries judged similar in their degree of underreporting. National and international experts provided their judgements of the magnitude of underreporting. In addition, for countries where reporting is sparse, but surveys have been performed, the published data were used as a basis to select the appropriate degree of underreporting [@pone.0035671-Reithinger1]. Wherever possible, estimated plausible VL and CL incidence ranges were assigned by country and/or region based on reported incidence and multiplication by the probable underreporting factors. Estimates less than 20 were retained as the precise product of the reported case number times the underreporting factor, those between 20 and 1000 were rounded to the nearest 10 and those over 1000 were rounded to the nearest 100. Where reporting was absent but incidence was known to be substantial, estimates were assigned based on the judgment of national and international experts. The regional estimates represent the sum of the country estimates followed by the same rounding process. Similarly, the global estimates represent the sum of the regional estimates followed by rounding as described above. In order to facilitate expert judgment regarding the probable accuracy of the figures presented here, we defined geographical regions consistent with the major ecological foci of leishmaniasis transmission, rather than official WHO regions [@pone.0035671-Ashford1], [@pone.0035671-Ashford2], [@pone.0035671-Shaw1].

A second questionnaire addressed access to antileishmanial medicines, and included specific questions: whether the public sector provides health care free of charge; the existence of a national program for control of leishmaniasis; inclusion of antileishmanial medicines in the National Essential Drug List; the number of different medicines purchased for the public sector or donations received in the last two years; sale of antileishmanial drugs in the private sector and price per tablet or vial; percentage of people using the for-profit private sector versus public sector for leishmaniasis treatment; health care level providing treatment in the public sector; presence of NGOs or other non-profit agencies providing leishmaniasis treatment; and barriers to access for treatment of leishmaniasis. Basic social and health data from each country were obtained from the websites of the relevant international agencies [@pone.0035671-World5], [@pone.0035671-World6], [@pone.0035671-United1], [@pone.0035671-World7], [@pone.0035671-InternationalMonetary1].

The epidemiological data were used to produce maps with 2008 as the reference year using ArcGIS 9.3-- Desktop (Esri, Redlands, CA) and following WHO guidelines for GIS usage. The numbers of confirmed cases by clinical form (VL, CL, mucocutaneous leishmaniasis) were mapped by official first level administrative division. These data were used to calculate annual incidence rates. A single standard range of values was used for each clinical form to facilitate visual comparison between countries. Draft maps were shared with data providers and other leishmaniasis experts for validation. The following maps were developed for each country: situational map with neighbouring countries and world globe, maps of cases by clinical form, and maps of incidence per 10,000 inhabitants. All maps follow a consistent set of characteristics: five categories of colours in a yellow-to-red scale were chosen for the maps of cases, and six categories of colours in blue tones scale were chosen for the maps of incidence. The sparse information in a few countries required the use of *ad hoc* scales. Only WHO GIS shapefile databases were used; the maps follow the administrative limits and frontiers recognized by United Nations conventions.

The parasitological information has been reproduced from the WHO Technical Report Series 949 (<http://whqlibdoc.who.int/trs/WHO_TRS_949_eng.pdf>) published in 2010.

Basic social and health data, results of literature reviews, data on the magnitude of underreporting, maps, data regarding epidemiology, case load, access to treatment and access to drugs, and parasitological information are presented in a series of extensive Profiles of each endemic individual country and territory and are presented in the Annex of this publication (see 'Leishmaniasis Country Profiles [Text S1](#pone.0035671.s001){ref-type="supplementary-material"}, [S2](#pone.0035671.s002){ref-type="supplementary-material"}, [S3](#pone.0035671.s003){ref-type="supplementary-material"}, [S4](#pone.0035671.s004){ref-type="supplementary-material"}, [S5](#pone.0035671.s005){ref-type="supplementary-material"}, [S6](#pone.0035671.s006){ref-type="supplementary-material"}, [S7](#pone.0035671.s007){ref-type="supplementary-material"}, [S8](#pone.0035671.s008){ref-type="supplementary-material"}, [S9](#pone.0035671.s009){ref-type="supplementary-material"}, [S10](#pone.0035671.s010){ref-type="supplementary-material"}, [S11](#pone.0035671.s011){ref-type="supplementary-material"}, [S12](#pone.0035671.s012){ref-type="supplementary-material"}, [S13](#pone.0035671.s013){ref-type="supplementary-material"}, [S14](#pone.0035671.s014){ref-type="supplementary-material"}, [S15](#pone.0035671.s015){ref-type="supplementary-material"}, [S16](#pone.0035671.s016){ref-type="supplementary-material"}, [S17](#pone.0035671.s017){ref-type="supplementary-material"}, [S18](#pone.0035671.s018){ref-type="supplementary-material"}, [S19](#pone.0035671.s019){ref-type="supplementary-material"}, [S20](#pone.0035671.s020){ref-type="supplementary-material"}, [S21](#pone.0035671.s021){ref-type="supplementary-material"}, [S22](#pone.0035671.s022){ref-type="supplementary-material"}, [S23](#pone.0035671.s023){ref-type="supplementary-material"}, [S24](#pone.0035671.s024){ref-type="supplementary-material"}, [S25](#pone.0035671.s025){ref-type="supplementary-material"}, [S26](#pone.0035671.s026){ref-type="supplementary-material"}, [S27](#pone.0035671.s027){ref-type="supplementary-material"}, [S28](#pone.0035671.s028){ref-type="supplementary-material"}, [S29](#pone.0035671.s029){ref-type="supplementary-material"}, [S30](#pone.0035671.s030){ref-type="supplementary-material"}, [S31](#pone.0035671.s031){ref-type="supplementary-material"}, [S32](#pone.0035671.s032){ref-type="supplementary-material"}, [S33](#pone.0035671.s033){ref-type="supplementary-material"}, [S34](#pone.0035671.s034){ref-type="supplementary-material"}, [S35](#pone.0035671.s035){ref-type="supplementary-material"}, [S36](#pone.0035671.s036){ref-type="supplementary-material"}, [S37](#pone.0035671.s037){ref-type="supplementary-material"}, [S38](#pone.0035671.s038){ref-type="supplementary-material"}, [S39](#pone.0035671.s039){ref-type="supplementary-material"}, [S40](#pone.0035671.s040){ref-type="supplementary-material"}, [S41](#pone.0035671.s041){ref-type="supplementary-material"}, [S42](#pone.0035671.s042){ref-type="supplementary-material"}, [S43](#pone.0035671.s043){ref-type="supplementary-material"}, [S44](#pone.0035671.s044){ref-type="supplementary-material"}, [S45](#pone.0035671.s045){ref-type="supplementary-material"}, [S46](#pone.0035671.s046){ref-type="supplementary-material"}, [S47](#pone.0035671.s047){ref-type="supplementary-material"}, [S48](#pone.0035671.s048){ref-type="supplementary-material"}, [S49](#pone.0035671.s049){ref-type="supplementary-material"}, [S50](#pone.0035671.s050){ref-type="supplementary-material"}, [S51](#pone.0035671.s051){ref-type="supplementary-material"}, [S52](#pone.0035671.s052){ref-type="supplementary-material"}, [S53](#pone.0035671.s053){ref-type="supplementary-material"}, [S54](#pone.0035671.s054){ref-type="supplementary-material"}, [S55](#pone.0035671.s055){ref-type="supplementary-material"}, [S56](#pone.0035671.s056){ref-type="supplementary-material"}, [S57](#pone.0035671.s057){ref-type="supplementary-material"}, [S58](#pone.0035671.s058){ref-type="supplementary-material"}, [S59](#pone.0035671.s059){ref-type="supplementary-material"}, [S60](#pone.0035671.s060){ref-type="supplementary-material"}, [S61](#pone.0035671.s061){ref-type="supplementary-material"}, [S62](#pone.0035671.s062){ref-type="supplementary-material"}, [S63](#pone.0035671.s063){ref-type="supplementary-material"}, [S64](#pone.0035671.s064){ref-type="supplementary-material"}, [S65](#pone.0035671.s065){ref-type="supplementary-material"}, [S66](#pone.0035671.s066){ref-type="supplementary-material"}, [S67](#pone.0035671.s067){ref-type="supplementary-material"}, [S68](#pone.0035671.s068){ref-type="supplementary-material"}, [S69](#pone.0035671.s069){ref-type="supplementary-material"}, [S70](#pone.0035671.s070){ref-type="supplementary-material"}, [S71](#pone.0035671.s071){ref-type="supplementary-material"}, [S72](#pone.0035671.s072){ref-type="supplementary-material"}, [S73](#pone.0035671.s073){ref-type="supplementary-material"}, [S74](#pone.0035671.s074){ref-type="supplementary-material"}, [S75](#pone.0035671.s075){ref-type="supplementary-material"}, [S76](#pone.0035671.s076){ref-type="supplementary-material"}, [S77](#pone.0035671.s077){ref-type="supplementary-material"}, [S78](#pone.0035671.s078){ref-type="supplementary-material"}, [S79](#pone.0035671.s079){ref-type="supplementary-material"}, [S80](#pone.0035671.s080){ref-type="supplementary-material"}, [S81](#pone.0035671.s081){ref-type="supplementary-material"}, [S82](#pone.0035671.s082){ref-type="supplementary-material"}, [S83](#pone.0035671.s083){ref-type="supplementary-material"}, [S84](#pone.0035671.s084){ref-type="supplementary-material"}, [S85](#pone.0035671.s085){ref-type="supplementary-material"}, [S86](#pone.0035671.s086){ref-type="supplementary-material"}, [S87](#pone.0035671.s087){ref-type="supplementary-material"}, [S88](#pone.0035671.s088){ref-type="supplementary-material"}, [S89](#pone.0035671.s089){ref-type="supplementary-material"}, [S90](#pone.0035671.s090){ref-type="supplementary-material"}, [S91](#pone.0035671.s091){ref-type="supplementary-material"}, [S92](#pone.0035671.s092){ref-type="supplementary-material"}, [S93](#pone.0035671.s093){ref-type="supplementary-material"}, [S94](#pone.0035671.s094){ref-type="supplementary-material"}, [S95](#pone.0035671.s095){ref-type="supplementary-material"}, [S96](#pone.0035671.s096){ref-type="supplementary-material"}, [S97](#pone.0035671.s097){ref-type="supplementary-material"}, [S98](#pone.0035671.s098){ref-type="supplementary-material"}, [S99](#pone.0035671.s099){ref-type="supplementary-material"}, [S100](#pone.0035671.s100){ref-type="supplementary-material"}, [S101](#pone.0035671.s101){ref-type="supplementary-material"}').

Results {#s3}
=======

A total of 98 countries and 3 territories on 5 continents reported endemic leishmaniasis transmission ([Tables 1](#pone-0035671-t001){ref-type="table"}, [2](#pone-0035671-t002){ref-type="table"}, [3](#pone-0035671-t003){ref-type="table"}, [4](#pone-0035671-t004){ref-type="table"}, [5](#pone-0035671-t005){ref-type="table"}, [6](#pone-0035671-t006){ref-type="table"} and [7](#pone-0035671-t007){ref-type="table"}, [8](#pone-0035671-t008){ref-type="table"}, [9](#pone-0035671-t009){ref-type="table"}, [10](#pone-0035671-t010){ref-type="table"}, [11](#pone-0035671-t011){ref-type="table"}, [12](#pone-0035671-t012){ref-type="table"}). In total, official case counts totalled more than 58,000 VL cases and 220,000 CL cases per year ([Tables 13](#pone-0035671-t013){ref-type="table"} and [14](#pone-0035671-t014){ref-type="table"}). However, only about two-thirds of countries had reported incidence data for a five-year period; data were sparsest for the foci in Africa. A number of countries are listed here as endemic despite the lack of reported human cases, usually reflecting an absence of surveillance or other investigations. [@pone.0035671-leFichoux1] For example, although Mongolia has not reported human CL cases, *L. major* genetically identical to that found in countries with proven endemic transmission has been isolated on multiple occasions from gerbils. [@pone.0035671-Neronov1] Only countries with circulating species known to be pathogenic to humans are included as endemic. For this reason, Australia is not considered endemic despite reports of CL among red kangaroos caused by a newly described leishmanial species. [@pone.0035671-Rose1] Human infections due to lower trypanosomatids are also excluded. [@pone.0035671-Chicharro1].

There are few published empirical assessments of underreporting in official surveillance data. Two studies from Bihar, India, compared VL case numbers ascertained through active house-to-house surveys to those reported in the official surveillance system; official figures were shown to be 4.2-fold and 8.1-fold lower than the incidence found by active case detection in the two studies, respectively. [@pone.0035671-Singh1], [@pone.0035671-Singh2] A study in Brazil used the capture-recapture method to estimate underreporting of VL, based on data from 3 different sources; the degree of underreporting was found to be 1.3- to 1.7-fold. [@pone.0035671-MaiaElkhoury1] Data from one province in Argentina estimated the degree of CL underreporting to be 2.8 to 4.6-fold; however, studies from Guatemala and Jordan indicate that CL incidence may be underestimated by 40- to 47-fold in national surveillance data. [@pone.0035671-Copeland1], [@pone.0035671-Mosleh1], [@pone.0035671-Yadon1] Based on these publications, country-level VL underreporting magnitude was categorized as follows: mild (1.2- to 1.8-fold based on data from Brazil [@pone.0035671-MaiaElkhoury1]); severe (4.0- to 8.0-fold based on data from India [@pone.0035671-Singh1], [@pone.0035671-Singh2]); and an intermediate category of moderate (2.0 to 4.0-fold) underreporting. Despite the high published range of CL underreporting [@pone.0035671-Copeland1], [@pone.0035671-Mosleh1], we chose conservative multipliers: mild (2.8 to 4.6-fold based on data from Argentina [@pone.0035671-Yadon1]) and moderate (5.0- to 10.0-fold). No estimates could be made for most countries in sub-Saharan Africa, where almost no data were available.

Based on these estimates, approximately 0.2 to 0.4 million VL cases and 0.7 to 1.2 million CL cases occur each year. More than 90% of global VL cases occur in just six countries: India, Bangladesh, Sudan, South Sudan, Brazil and Ethiopia ([Table 13](#pone-0035671-t013){ref-type="table"}). Cutaneous leishmaniasis is more widely distributed, with about one-third of cases occurring in each of three regions, the Americas, the Mediterranean basin, and western Asia from the Middle East to Central Asia ([Table 14](#pone-0035671-t014){ref-type="table"}). The ten countries with the highest estimated case counts, Afghanistan, Algeria, Colombia, Brazil, Iran, Syria, Ethiopia, North Sudan, Costa Rica and Peru, together account for 70 to 75% of global estimated CL incidence.

Mortality data are extremely sparse and generally represent hospital-based deaths only. The reported case-fatality rate for VL in Brazil in 2006 was 7.2%. In the Indian subcontinent, the focus responsible for the largest proportion of global VL cases, reported case-fatality rates ranged from 1.5% (93 deaths/6224 VL cases from 2004--2008) in Bangladesh to 2.4% (853/34,918) in India and 6.2% (91/1477) in Nepal. However, community-based studies that included active searches for deaths due to kala-azar estimate case-fatality rates of more than 10%, while data from a village-based study in India suggest that as many as 20% of VL patients, disproportionately poor and female, died before their disease was recognized. [@pone.0035671-Ahluwalia1], [@pone.0035671-Kumar1], [@pone.0035671-Barnett1] In South Sudan, one community-based longitudinal study demonstrated a case-fatality rate of 20% in a settled village in peacetime; in areas of conflict, famine or population displacement mortality rates are much higher. [@pone.0035671-Zijlstra1], [@pone.0035671-Seaman1] A recent study from South Sudan estimated that 91% of all kala-azar deaths went unrecognized. [@pone.0035671-Collin2] Using an overall case-fatality rate of 10% and assuming that virtually all deaths are from VL, we reach a tentative estimate of 20,000 to 40,000 leishmaniasis deaths per year, in line with previous WHO estimates. [@pone.0035671-World3]

Discussion {#s4}
==========

The data presented here and in the accompanying Annex (see 'Leishmaniasis Country Profiles [Text S1](#pone.0035671.s001){ref-type="supplementary-material"}--[S101](#pone.0035671.s101){ref-type="supplementary-material"}') represent the first update of the empirical database for leishmaniasis since 1991. [@pone.0035671-Ashford3], [@pone.0035671-Desjeux3] We are acutely cognizant of the uncertainties inherent in the data, and for that reason, have presented rough ranges rather than single estimates for each outcome. We deliberately used conservative assumptions for the underreporting rates and resultant multipliers; true leishmaniasis incidence rates may be substantially higher. Due to the lack of data, we made no estimates for post-kala-azar dermal leishmaniasis, mucocutaneous leishmaniasis, and other less frequent forms of leishmaniasis. Our mortality estimate contains even more uncertainty than the incidence estimate, because studies affirm that a large proportion of kala-azar deaths occur outside of health facilities and the cause likely never recognized, precluding the possibility of accurate passive reporting. [@pone.0035671-Ahluwalia1], [@pone.0035671-Barnett1], [@pone.0035671-Collin2].

The limitations of these data are obvious: surveillance and vital records reporting in the countries most affected by leishmaniasis are incomplete, and we have very sparse data on which to base correction factors for underreporting. The figures in this report should not be considered precise and should be interpreted with caution. Nevertheless, these data include a more comprehensive review of leishmaniasis incidence than any previous publication, and represent a major improvement in the evidence base for one of the most neglected diseases. [@pone.0035671-Yamey1] Better surveillance systems are urgently needed, in particular in disease foci targeted for more intensive control or elimination. [@pone.0035671-Bern1], [@pone.0035671-Narain1] Many key measures of progress, such as validation of trends seen in surveillance data and accurate case-fatality rates, can only be obtained through the active collection of community-based data. [@pone.0035671-Bern1], [@pone.0035671-Hirve1] We hope the data presented here will allow a more nuanced interpretation of published disease burden estimates, and the uncertainties in these data will spur activities to improve the evidence base for leishmaniasis and other neglected diseases.
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